var data={"title":"Betahistine (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Betahistine (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5730?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=betahistine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Betahistine (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140528\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Act Betahistine;</li>\n      <li>Auro-Betahistine;</li>\n      <li>pms-Betahistine;</li>\n      <li>Serc;</li>\n      <li>Teva-Betahistine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140561\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Histamine H<sub>1</sub> Agonist;</li>\n      <li>\n        Histamine H<sub>3</sub> Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140531\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>M&eacute;ni&egrave;re disease (to decrease episodes of vertigo):</b> Oral: 8 to 16 mg 3 times daily or 24 mg twice daily; usual dosage range: 24 to 48 mg daily in divided doses. Doses slowly titrated (ie, approximately every 3 months) up to 480 mg daily (off-label dosing) have been reported in a small number of cases with severe, resistant disease (Lezius 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062964\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution due to likelihood of decreased hepatic/renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682288\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682289\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Betahistine primarily undergoes hepatic metabolism; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120616\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral, as dihydrochloride: 8 mg, 16 mg, 24 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217334\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140514\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with or without meals; administer with meals if adverse GI effects occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140513\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>M&eacute;ni&egrave;re disease:</b> Treatment of M&eacute;ni&egrave;re disease (to decrease episodes of vertigo)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140505\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (2%), dyspepsia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Confusion, convulsions, drowsiness (case reports), hallucination, paraesthesia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypotension (including orthostatic and postural hypotension), tachycardia, ventricular premature contractions (case reports) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pruritus, skin rash, Stevens-Johnson syndrome, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal distension, abdominal pain, bloating, peptic ulcer (including exacerbation of previous disease), vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140517\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to betahistine or any component of the formulation; presence or history of active peptic ulcer disease; pheochromocytoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140503\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Asthma: Use with caution; clinical intolerance has been reported in a few asthmatic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; post-market cases of ventricular extrasystoles, hypotension, and tachycardia have been reported during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution; primarily undergoes hepatic metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peptic ulcer: Exacerbation of symptoms has been observed in patients with a history of peptic ulcer; use is contraindicated in the presence or history of peptic ulcer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298856\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140507\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8694&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antihistamines: May diminish the therapeutic effect of Betahistine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Betahistine may diminish the therapeutic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May increase the serum concentration of Betahistine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140519\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16248949\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if betahistine is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13121044\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Partial agonist of histamine at H<sub>1</sub> receptor and antagonist at H<sub>3</sub> receptor; relatively inactive at H<sub>2</sub> receptor. Animal studies suggest that betahistine may increase cochlear blood flow and produce excitatory effects on neuronal activity of cortical and subcortical structures via H<sub>1</sub>-receptor agonism and decrease vestibular sensory input and increase synthesis and release of histamine from the hypothalamus via H<sub>3</sub>-receptor antagonism (Ihler 2012; Lacour 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140516\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid, complete; delayed by food </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">T<sub>max</sub>: 1 hour to reach peak levels of inactive metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapid and almost complete hepatic metabolism to 2-pyridylacetic acid (inactive metabolite) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~3.5 hours (inactive metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~91%; primarily as inactive metabolite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140521\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aequamen (DE);</li>\n      <li>Agihistine (VN);</li>\n      <li>Agiserc (IL);</li>\n      <li>Alfinor (HK, LK, MY);</li>\n      <li>Alvigo (LB);</li>\n      <li>Beautipex (KR);</li>\n      <li>Behistin (TH);</li>\n      <li>Besutin (TW);</li>\n      <li>Betagen (AE, QA);</li>\n      <li>Betahist (LK);</li>\n      <li>Betahistine-Eurogenerics (LU);</li>\n      <li>Betasaerc (JO);</li>\n      <li>Betaserc (AE, AT, BE, BG, BH, BR, CH, CY, CZ, DK, EC, EE, EG, FI, GR, HK, HN, HR, HU, ID, KW, LK, LT, LU, LV, MT, MY, NL, PE, PH, PL, PT, QA, RO, RU, SA, SG, SI, TR, TW, TZ, VN);</li>\n      <li>Betaserk (UA);</li>\n      <li>Betastin (JO);</li>\n      <li>Betavert (BD, PH);</li>\n      <li>Betistin (UY);</li>\n      <li>Betris (TH);</li>\n      <li>By-Vertin (IE);</li>\n      <li>Clensan (TW);</li>\n      <li>Ergo (PH);</li>\n      <li>Exigo (PH);</li>\n      <li>Fidium (ES);</li>\n      <li>Histigo (ID, TH);</li>\n      <li>Kernhistine (VN);</li>\n      <li>Kurtigo (ID);</li>\n      <li>Lectil (FR);</li>\n      <li>Lexigo (ID);</li>\n      <li>Lobione (LU);</li>\n      <li>Makshistyn (UA);</li>\n      <li>Menaril (BD);</li>\n      <li>Meniace (JP, KR);</li>\n      <li>Menistin (PE);</li>\n      <li>Merislon (CN, CR, DO, GT, HK, ID, JP, MY, PH, SG, SV, TH, TW, VN);</li>\n      <li>Merison (HK);</li>\n      <li>Meristin (ID);</li>\n      <li>Mertigo (ID, TH);</li>\n      <li>Meslon (TW);</li>\n      <li>Microser (AR, CL, EC, IT, PE, PK, VE);</li>\n      <li>Misoserc (QA);</li>\n      <li>Nisulin (TW);</li>\n      <li>Novertin (PY);</li>\n      <li>Novirex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Nuveat (PH);</li>\n      <li>Rotaver (ID);</li>\n      <li>Seniere (AU);</li>\n      <li>Serc (AU, GB, HR, IE, MX, NZ, PK, TH, ZA);</li>\n      <li>Stei (TH);</li>\n      <li>Suzutolon (JP);</li>\n      <li>Theohist (LK);</li>\n      <li>Tiniril (BD);</li>\n      <li>Urutal (HR);</li>\n      <li>Vasomotal (DE, PY);</li>\n      <li>Vasoserc (LB);</li>\n      <li>Vasoserc Forte (LB);</li>\n      <li>Vasotal (UY);</li>\n      <li>Verdiz (PH);</li>\n      <li>Vergo (NZ);</li>\n      <li>Vert (PH);</li>\n      <li>Vertigal (HR);</li>\n      <li>Vertigon (IE);</li>\n      <li>Vertihof (TH);</li>\n      <li>Vertikind (PH);</li>\n      <li>Vertimed (MT, RO, TR);</li>\n      <li>Vertin (IN);</li>\n      <li>Vertinex (LB);</li>\n      <li>Vertrol (PH);</li>\n      <li>Verum (CO);</li>\n      <li>Vestibo (UA);</li>\n      <li>Veszrc (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ihler F, Bertlich M, Sharaf K, et al. Betahistine Exerts a Dose-Dependent Effect on Cochlear Stria Vascularis Blood Flow in Guinea Pigs In Vivo. <i>PLoS One</i>. 2012;7(6):e39086.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betahistine-united-states-not-available-drug-information/abstract-text/22745706/pubmed\" target=\"_blank\" id=\"22745706\">22745706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lacour M, van de Heyning PH, Novotny M, et al. Betahistine in the treatment of M&eacute;ni&egrave;re&rsquo;s disease. <i>Neuropsychiatr Dis Treat.</i> 2007;3(4):429-440.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betahistine-united-states-not-available-drug-information/abstract-text/19300572/pubmed\" target=\"_blank\" id=\"19300572\">19300572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lezius F, Adrion C, Mansmann U, et al. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Meni&eacute;re&rsquo;s disease: a case series. <i>Eur Arch Otorhinolaryngol</i>. 2011;268(8):1237-1240.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betahistine-united-states-not-available-drug-information/abstract-text/21626121/pubmed\" target=\"_blank\" id=\"21626121\">21626121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serc (betahistine) [product monograph].Etobicoke, Ontario, Canada: BGP Pharma ULC: August 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8694 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F140528\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F140561\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F140531\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062964\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15682288\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682289\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F8120616\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11217334\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F140514\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F140513\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F140505\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F140517\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F140503\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298856\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F140507\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F140519\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16248949\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13121044\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F140516\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F140521\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8694|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=betahistine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Betahistine (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}